Patents by Inventor Anastassios D. Retzios

Anastassios D. Retzios has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nasal administration of agents for the treatment of gastroparesis
    Patent number: 6770262
    Abstract: The present invention is directed to a method for the treatment of gastroparesis by the use of metoclopramide nasal formulation.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: August 3, 2004
    Assignee: Questcor Pharmaceuticals, Inc.
    Inventors: Laura S. Lehman, David Tierney, Anastassios D. Retzios, Michael Petrone, David Young, Carol B. Trapnell, Ruth Oliver
  • Nasal administration of agents for the treatment of gastroparesis
    Publication number: 20030059374
    Abstract: The present invention is directed to a method for the treatment of gastroparesis by the use of metoclopramide nasal formulation.
    Type: Application
    Filed: August 15, 2002
    Publication date: March 27, 2003
    Inventors: Laura S. Lehman, David Tierney, Anastassios D. Retzios, Michael Petrone, David Young, Carol B. Trapnell, Ruth Oliver
  • Nasal administration of agents for the treatment of gastroparesis
    Publication number: 20020065321
    Abstract: The present invention is directed to a method for the treatment of gastroparesis by the use of metoclopramide nasal formulation.
    Type: Application
    Filed: March 29, 2001
    Publication date: May 30, 2002
    Inventors: Laura S. Lehman, David Tierney, Anastassios D. Retzios, Michael Petrone, David Young, Carol B. Trapnell, Ruth Oliver
  • Fibrinolytic enzymes
    Patent number: 5260060
    Abstract: Novel fibrinolytic zinc metalloproteinases exhibiting direct fibrinolytic activity in plasminogen free systems, no detectable plasminogen activation activity in vitro, and no observable systemic toxicity in vivo as exemplified by the absence of hemorrhagic activity, characterized by peptide bond cleavage specificities which are markedly different from those of the heretofore identified metalloproteinases. Several of the enzymes are further characterized by substantially reduced proteolytic activity (as measured by azocaseinolytic activity in vitro) relative to A.c.contortrix fibrolase. The novel fibrinolytic enzymes with reduced proteolytic activity generally exhibit levels of proteolytic activity less than about 70% of that exhibited by a fibrinolytic enzyme having the activity profile of the enzyme as isolated from A.c.contortrix venom.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: November 9, 1993
    Assignee: University of Southern California
    Inventors: Francis S. Markland, Jr., Anastassios D. Retzios